Liver Testing Through a New Investigative Tool
HepQuant: A minimally invasive assessment of chronic liver disease
A New Investigative Tool to Evaluate the Liver
Backed by years of data
assessment of chronic liver disease
Novel technology for minimally invasive
Breaking Through Conventional Thinking About Liver Testing
HepQuant is a privately-held, early-stage medical diagnostics company with unique, patented and patent-pending technology for assessing liver function of patients with chronic liver disease. HepQuant technologies, licensed from the University of Colorado Denver (UCD), have been advanced with the intent to profoundly impact the liver disease landscape – including the research, treatment and patient communities – with diagnostic products that are accurate and minimally invasive.
HepQuant’s Participation at The Liver Meeting
HepQuant conducting an oral presentation and presenting three posters at the The Liver Meeting® 2017 in Washington DC, October 20 – 24, 2017. Here is a link to our presentation on “Diagnosing NASH and Assessing NASH Disease Severity with HepQuant-STAT, a Simple Quantitative Liver Function Test.” We also presented a poster entitled: Portal-Systemic Shunt Fraction measured by the HepQuant-SHUNT Test Correlates with the Hepatic Venus Pressure Gradient (HVPG).